These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28679776)

  • 1. Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma.
    Mell LK; Brumund KT; Daniels GA; Advani SJ; Zakeri K; Wright ME; Onyeama SJ; Weisman RA; Sanghvi PR; Martin PJ; Szalay AA
    Clin Cancer Res; 2017 Oct; 23(19):5696-5702. PubMed ID: 28679776
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.
    Lauer UM; Schell M; Beil J; Berchtold S; Koppenhöfer U; Glatzle J; Königsrainer A; Möhle R; Nann D; Fend F; Pfannenberg C; Bitzer M; Malek NP
    Clin Cancer Res; 2018 Sep; 24(18):4388-4398. PubMed ID: 29773661
    [No Abstract]   [Full Text] [Related]  

  • 3. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
    Herchenhorn D; Dias FL; Viegas CM; Federico MH; Araújo CM; Small I; Bezerra M; Fontão K; Knust RE; Ferreira CG; Martins RG
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):696-702. PubMed ID: 20421154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.
    Harrington KJ; Hingorani M; Tanay MA; Hickey J; Bhide SA; Clarke PM; Renouf LC; Thway K; Sibtain A; McNeish IA; Newbold KL; Goldsweig H; Coffin R; Nutting CM
    Clin Cancer Res; 2010 Aug; 16(15):4005-15. PubMed ID: 20670951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
    Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma.
    de Castro G; Snitcovsky IM; Gebrim EM; Leitão GM; Nadalin W; Ferraz AR; Federico MH
    Eur Arch Otorhinolaryngol; 2007 Dec; 264(12):1475-82. PubMed ID: 17643256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Recchia F; Saggio G; Cesta A; Amiconi G; di Blasio A; Candeloro G; Valeriani M; Tombolini V; Rea S
    Anticancer Res; 2006; 26(3B):2317-24. PubMed ID: 16821609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
    Kohno N; Kitahara S; Tamura E; Tanabe T
    Oncology; 2002; 63(3):226-31. PubMed ID: 12381901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. concomitant chemoradiotherapy with mitomycin C and cisplatin in advanced unresectable carcinoma of the head and neck: phase I-II clinical study.
    Strojan P; Karner K; Smid L; Soba E; Fajdiga I; Jancar B; Anicin A; Budihna M; Zakotnik B
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):365-72. PubMed ID: 18394816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
    Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V; Lewin J; Clayman GL; Ang KK; Glisson BS
    J Clin Oncol; 2006 Sep; 24(25):4163-9. PubMed ID: 16943532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
    Colevas AD; Busse PM; Norris CM; Fried M; Tishler RB; Poulin M; Fabian RL; Fitzgerald TJ; Dreyfuss A; Peters ES; Adak S; Costello R; Barton JJ; Posner MR
    J Clin Oncol; 1998 Apr; 16(4):1331-9. PubMed ID: 9552034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.
    Fesneau M; Pointreau Y; Chapet S; Martin L; Pommier P; Alfonsi M; Laguerre B; Feham N; Berger C; Garaud P; Calais G
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):154-63. PubMed ID: 19386430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
    Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
    Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
    Caponigro F; Comella P; Marcolin P; Russo Spena F; Biglietto M; Cartenì G; De Lucia L; Avallone A; Gravina A; Comella G
    Cancer; 1999 Feb; 85(4):952-9. PubMed ID: 10091775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
    Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.